期刊文献+

帕金森病认知功能障碍的调查研究 被引量:15

Investigation of cognitive dysfunction of parkinson disease
暂未订购
导出
摘要 目的:应用蒙特利尔认知评估(MoCA)量表探讨帕金森患者认知功能障碍。方法:选择2006年12月~2007年12月我院散发性帕金森病患者101例,将帕金森病痴呆患者作为病例组(n=53),将帕金森病非痴呆患者作为对照组(n=48)。采用问卷调查方法,问卷内容包括患者的基线信息;采用UPDRS评分及H-Y分级评价帕金森病的程度。采用MMSE、MoCA及画钟试验进行认知功能评估并对结果进行统计分析。结果:病例组认知功能的视空间、注意力、延迟记忆及计算力得分明显低于对照组(P<0.05)。结论:MoCA量表有利于发现帕金森患者的认知功能障碍。 Objective:To investigate the cognitive dysfunction of patients with parkinson disease(PD) by the application of Montreal cognitive assessment(MoCA) scale.Methods:101 cases of patients with PD in our hospital from December 2006 to December 2007 were selected.PD patients with dementia were divided into case group(n=53),and PD patients without dementia were divided into control group(n=48).Method of questionnaire survey was adopted to investigate the baseline information of patients.UPDRS grade and H-Y grading evaluation of the PD degree were included in the questionnaire.MMSE,MoCA and painting clock experiment were used to assess the cognitive function and the results were analyzed.Results:The scores of visual space,attention,delayed recall and calculation ability of case group were lower than those of control group,the differences were statistically significant(P0.05).Conclusion:Cognitive dysfunction of PD patients can be found more easily by MoCA scale.
作者 栗莉
出处 《中国医药导报》 CAS 2011年第36期143-145,共3页 China Medical Herald
关键词 帕金森病 痴呆 认知功能障碍 Parkinson disease Dementia Cognitive dysfunction
  • 相关文献

参考文献10

二级参考文献12

  • 1杜芳,李锐,黄远桂,乐卫东.普拉克索和罗匹尼罗对体外培养的多巴胺神经元的神经营养作用[J].中国新药与临床杂志,2004,23(8):504-509. 被引量:7
  • 2温洪波,张振馨,罗毅,陈生弟,蒋雨平,张小英,孙相如,王新德,姚晨.普拉克索治疗帕金森病的多中心、随机、双盲、溴隐亭对照临床疗效和安全性研究[J].中华神经科杂志,2006,39(9):604-608. 被引量:63
  • 3Schapira AH. Present and future drug treatment for Parkinson's [J]. J Neurol Neumsurg Psychiatry,2005,76(11}:1472-1478.
  • 4Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study [J]. Neurology, 2006,67( 17): 1225-1227.
  • 5Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertralinein the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study [J]. J Neurol,2006,253(5):601-607.
  • 6Izumi Y, Sawada H, Yamamoto N, et al. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine- mediated excitotoxicity [J]. Eur J Pharmacot,2007,557(2-3):132-140.
  • 7Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease [J]. Mov Disord,2003,18(10):1149-1156.
  • 8Hamidovic A, Kang UJ,de Wit H. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers [J]. J Clin Psychopharmacol,2008,28(1):45-51.
  • 9Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole [J]. J Neuroehem,2003,87(3):631-641.
  • 10刘凌,李娟.关于普拉克索治疗晚期帕金森病的临床研究[J].中国医药导报,2008,5(16):59-60. 被引量:25

共引文献118

同被引文献191

引证文献15

二级引证文献229

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部